What is the clinical evidence from this study?

Study design: Other. Population: Acute coronary syndrome (n=1000). Intervention: Ticagrelor vs. Standard 90 mg twice daily vs 60 mg twice daily. Primary outcome: Steady-state minimum concentration (Cmin,ss) and pharmacokinetic parameters.

What question did this study set out to answer?

This analysis aims to develop a population pharmacokinetic model of ticagrelor for optimal dosing in acute coronary syndrome.

July 14, 2026Scientific Reports0 citationsOpen Access

A pooled population pharmacokinetic analysis of ticagrelor in acute coronary syndrome using simulated data

JLJi Woo LimYonsei University HKH C KimYonsei University HKHeungjo KimYonsei University

Key Result

Simulations demonstrated that elderly patients and smokers receiving ticagrelor 90 mg twice-daily frequently exceeded the upper safety threshold, whereas 60 mg twice-daily maintained target exposure.

Key Points

This analysis aims to develop a population pharmacokinetic model of ticagrelor for optimal dosing in acute coronary syndrome.
Integrated pharmacokinetic model developed using pooled synthetic datasets from previous studies.
Virtual cohorts of 1,000 individuals were created, factoring in age, sex, weight, and smoking status.
Used a one-compartment model with a parent–metabolite relationship to describe ticagrelor and its active metabolite.
Ticagrelor Ka estimated at 0.613 h⁻¹, oral clearance at 13.3 L/h, and volume of distribution at 228 L.
Elderly patients and smokers on 90 mg twice-daily exceeded the upper safety threshold (Cmin, ss > 360 ng/mL).
A regimen of 60 mg twice-daily maintained exposure within the therapeutic range (180–360 ng/mL).

Structured PICO

Does a 60 mg twice-daily ticagrelor regimen maintain exposure within the target therapeutic range compared to 90 mg twice-daily in simulated ACS patients?

Population

1,000 virtual patients with acute coronary syndrome, generated from published pharmacokinetic models, simulated over 144 hours to evaluate ticagrelor dosing regimens.

Intervention

Ticagrelor (simulated regimens of 90 mg twice-daily and 60 mg twice-daily)

Outcome

Pharmacokinetic parameters (Ka, oral clearance, apparent volume of distribution) and simulated exposure levels (Cmin, ss)surrogate

Simulated pharmacokinetic modeling suggests that a 60 mg twice-daily dose of ticagrelor may be safer and maintain therapeutic exposure in elderly patients and smokers with ACS compared to the standard 90 mg twice-daily dose.

Limitations

Relies on data obtained from published literature, which may introduce inherent biases and variability
Absence of direct pharmacodynamic measurements in synthetic cohorts limits ability to model individual variability in platelet response
Covariate selection was limited to those consistently reported across identified source studies
Exposure thresholds have inherent uncertainties as they were derived from PK-PD modeling rather than direct ischemic outcome data
Relies entirely on synthetic data, precluding de novo covariate building or identification of novel sources of variability

Abstract

Ticagrelor is a P2Y12 inhibitor used to reduce thrombotic events in acute coronary syndrome (ACS). Optimal dosing is crucial for preventing bleeding and thrombosis; therefore, we developed the population pharmacokinetics (PK) of ticagrelor by incorporating results from previous population PK studies. Studies were identified through a PubMed search, and an integrated PK model was developed using pooled synthetic datasets. Two published PK models generated virtual cohorts of 1,000 individuals each with covariates of age, sex, weight, and smoking status. A one-compartment model with a parent–metabolite relationship was used to describe ticagrelor and its active metabolite. The final model estimated ticagrelor Ka at 0.613 h⁻¹, oral clearance (CL/F) at 13.3 L/h and apparent volume of distribution (Vd/F) of 228 L; the metabolite showed oral clearance (CLM/F) of 9.75 L/h and apparent volume of distribution (VM/F) of 4.59 L. Simulations showed that elderly patients and smokers receiving 90 mg twice-daily frequently exceeded the upper safety threshold (Cmin, ss > 360 ng/mL), whereas a 60 mg twice-daily regimen maintained exposure within the target therapeutic range (180–360 ng/mL). These hypothesis-generating findings warrant prospective validation in diverse ACS populations.

问 AI

Bookmark

View Full Paper